RHHBY - Why Is European Pharma Giant Argenx Valued At Over $20B Trading Higher On Thursday? | Benzinga
Thursday, Argenx SE (NASDAQ:ARGX) shares are trading higher in reaction to Chugai Pharmaceutical Co Ltd’s disappointing generalized myasthenia gravis trial, pushing the company’s market cap to $21.2 billion as per data from Benzinga Pro.
In June 2023, the FDA approved Argenx’s Vyvgart Hytrulo, an injection for subcutaneous (SC) use for generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor antibody positive. These patients represent approximately 85% of the total gMG population.
Vyvgart intravenous injection for gMG was approved in December 2021.